Ihuman Inc Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Ihuman Inc has an operating margin of 7.8%, meaning the company retains $8 of operating profit per $100 of revenue. This results in a moderate score of 39/100, indicating healthy but not exceptional operating efficiency. This is down from 15.7% the prior year.
Ihuman Inc's revenue declined 11.9% year-over-year, from $143.4M to $126.3M. This contraction results in a growth score of 0/100.
Ihuman Inc carries a low D/E ratio of 0.48, meaning only $0.48 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 93/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.98, Ihuman Inc holds $2.98 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 99/100.
Ihuman Inc's free cash flow margin of 5.5% results in a low score of 28/100. Capital expenditures of $1.0M absorb a large share of operating cash flow.
Ihuman Inc's ROE of 10.3% shows moderate profitability relative to equity, earning a score of 41/100. This is down from 18.9% the prior year.
Ihuman Inc scores 2.50, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.
Ihuman Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Ihuman Inc generates $0.59 in operating cash flow ($8.0M OCF vs $13.5M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
This page shows Ihuman Inc (IH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Ihuman Inc generated $126.3M in revenue in fiscal year 2024. This represents a decrease of 11.9% from the prior year.
Ihuman Inc's EBITDA was $11.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 51.5% from the prior year.
Ihuman Inc generated $7.0M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 70.0% from the prior year.
Ihuman Inc reported $13.5M in net income in fiscal year 2024. This represents a decrease of 47.0% from the prior year.
Ihuman Inc earned $0.05 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 44.4% from the prior year.
Ihuman Inc held $153.9M in cash against $0 in long-term debt as of fiscal year 2024.
Ihuman Inc's gross margin was 69.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 1.4 percentage points from the prior year.
Ihuman Inc's operating margin was 7.8% in fiscal year 2024, reflecting core business profitability. This is down 7.9 percentage points from the prior year.
Ihuman Inc's net profit margin was 10.7% in fiscal year 2024, showing the share of revenue converted to profit. This is down 7.1 percentage points from the prior year.
Ihuman Inc's ROE was 10.3% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 8.6 percentage points from the prior year.
Ihuman Inc invested $33.9M in research and development in fiscal year 2024. This represents a decrease of 6.4% from the prior year.
Ihuman Inc spent $1.3M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 1.9% from the prior year.
Ihuman Inc invested $1.0M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 11.2% from the prior year.
IH Income Statement
| Metric | Q4'24 | Q4'23 | Q4'22 | Q4'21 | Q4'20 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A |
IH Balance Sheet
| Metric | Q4'24 | Q4'23 | Q4'22 | Q4'21 | Q4'20 |
|---|---|---|---|---|---|
| Total Assets | $194.5M-4.8% | $204.3M+5.7% | $193.3M+11.9% | $172.8M+7.7% | $160.5M |
| Current Assets | $183.0M-6.0% | $194.7M+7.1% | $181.8M+14.1% | $159.3M+1.8% | $156.5M |
| Cash & Equivalents | $153.9M-10.0% | $171.0M+12.3% | $152.2M+13.4% | $134.2M+1.6% | $132.1M |
| Inventory | $3.2M+38.2% | $2.3M-16.1% | $2.8M-37.0% | $4.4M+70.2% | $2.6M |
| Accounts Receivable | $7.1M-16.8% | $8.6M-25.8% | $11.5M+31.1% | $8.8M-26.3% | $11.9M |
| Goodwill | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $62.9M-9.4% | $69.4M-15.1% | $81.8M+5.8% | $77.3M+24.7% | $62.0M |
| Current Liabilities | $61.3M-11.3% | $69.1M-15.0% | $81.3M+7.3% | $75.8M+23.9% | $61.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $131.6M-2.4% | $134.9M+20.9% | $111.6M+16.9% | $95.5M-3.1% | $98.5M |
| Retained Earnings | -$5.8M+70.8% | -$19.8M+57.5% | -$46.6M+29.9% | -$66.4M-12.2% | -$59.2M |
IH Cash Flow Statement
| Metric | Q4'24 | Q4'23 | Q4'22 | Q4'21 | Q4'20 |
|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A |
IH Financial Ratios
| Metric | Q4'24 | Q4'23 | Q4'22 | Q4'21 | Q4'20 |
|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | 2.98+0.2 | 2.82+0.6 | 2.23+0.1 | 2.10-0.5 | 2.56 |
| Debt-to-Equity | 0.48-0.0 | 0.51-0.2 | 0.73-0.1 | 0.81+0.2 | 0.63 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Ihuman Inc's annual revenue?
Ihuman Inc (IH) reported $126.3M in total revenue for fiscal year 2024. This represents a -11.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Ihuman Inc's revenue growing?
Ihuman Inc (IH) revenue declined by 11.9% year-over-year, from $143.4M to $126.3M in fiscal year 2024.
Is Ihuman Inc profitable?
Yes, Ihuman Inc (IH) reported a net income of $13.5M in fiscal year 2024, with a net profit margin of 10.7%.
What is Ihuman Inc's earnings per share (EPS)?
Ihuman Inc (IH) reported diluted earnings per share of $0.05 for fiscal year 2024. This represents a -44.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Ihuman Inc's EBITDA?
Ihuman Inc (IH) had EBITDA of $11.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Ihuman Inc's gross margin?
Ihuman Inc (IH) had a gross margin of 69.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Ihuman Inc's operating margin?
Ihuman Inc (IH) had an operating margin of 7.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Ihuman Inc's net profit margin?
Ihuman Inc (IH) had a net profit margin of 10.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Ihuman Inc's return on equity (ROE)?
Ihuman Inc (IH) has a return on equity of 10.3% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Ihuman Inc's free cash flow?
Ihuman Inc (IH) generated $7.0M in free cash flow during fiscal year 2024. This represents a -70.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Ihuman Inc's operating cash flow?
Ihuman Inc (IH) generated $8.0M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Ihuman Inc's total assets?
Ihuman Inc (IH) had $194.5M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Ihuman Inc's capital expenditures?
Ihuman Inc (IH) invested $1.0M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Ihuman Inc spend on research and development?
Ihuman Inc (IH) invested $33.9M in research and development during fiscal year 2024.
Does Ihuman Inc buy back shares?
Yes, Ihuman Inc (IH) spent $1.3M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
What is Ihuman Inc's current ratio?
Ihuman Inc (IH) had a current ratio of 2.98 as of fiscal year 2024, which is generally considered healthy.
What is Ihuman Inc's debt-to-equity ratio?
Ihuman Inc (IH) had a debt-to-equity ratio of 0.48 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Ihuman Inc's return on assets (ROA)?
Ihuman Inc (IH) had a return on assets of 6.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Ihuman Inc's Altman Z-Score?
Ihuman Inc (IH) has an Altman Z-Score of 2.50, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Ihuman Inc's Piotroski F-Score?
Ihuman Inc (IH) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Ihuman Inc's earnings high quality?
Ihuman Inc (IH) has an earnings quality ratio of 0.59x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Ihuman Inc?
Ihuman Inc (IH) scores 50 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.